Omvoh™ ,
Mirikizumab-mrkz
Disease
Ulcerative colitis
,
Drug Class
Biologics/Biosimilars
Delivery Method
IV
or
Injection
or
Brand name:
Omvoh™
,
Drug name:
Mirikizumab-mrkz
Drug type
Interleukin-23 Antagonist
Recommendations for pregnancy
Insufficient trial data. Monoclonal antibodies may be transported across the placenta.
Recommendations for breastfeeding
No human data.
Most common side effects
Induction: upper respiratory tract infections and arthralgia.
Maintenance: upper respiratory tract infections, injection site reactions, arthralgia, rash, headache, and herpes viral infection
Other
Rare side effects include: hypersensitivity reactions (anaphylaxis), infections, liver injury. Do not take Omvoh if you have active TB. Avoid use of live vaccines.
Learn more about
Biologics/Biosimilars